[Treatment of idiopathic fibrosing alveolitis. Therapeutic experiences with azathioprine-prednisolone and D-penicillamine-prednisolone combination therapy].
Lung function data during three different therapies for idiopathic fibrosing alveolitis are presented. Corticosteroid monotherapyis without effect. A combination of prednisolone and azathioprin improves vital capacity by more than 15% in half of cases. Under this treatment the resting PO2 improves in a third of patients. No improvement in PO2 under exercise is observable in any patient. Combined therapy with D-penicillamine and prednisolone improves vital capacity and PO2 both at rest and under exercise; this therapy thus appears to be superior to the other two. The effectiveness of D-penicillamine-prednisolone therapy can be enhanced by adding azathioprin, as has been found in a pilot study thus far covering 4 patients.
D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use*; D002199:Capillary Permeability / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use*; D011658:Pulmonary Fibrosis / Q000188:drug therapy*; D014797:Vital Capacity / Q000187:drug effects
D011239:Prednisolone; D010396:Penicillamine; D001379:Azathioprine
Behandlung der idiopathisch fibrosierenden Alveolitis. Therapeutische Erfahrungen mit einer Azathioprin-Prednisolon- sowie einer D-Penicillamin-Prednisolon-Kombinationstherapie